C.A.R.P., Canada’s largest advocacy association for Canadians As We Age, announces an exclusive partnership with Opticann by Heritage, a leading cannabis company offering evidence-based innovative products for medical cannabis patients in Canada. In conjunction with the partnership, C.A.R.P, ZoomerMedia Limited and Opticann will be creating tailored education for the 320,000+ C.A.R.P. members through C.A.R.P. affiliate ZoomerMedia’s TV, radio, print, and digital channels including VisionTV, The New Classical FM, Zoomer Radio, and Zoomer Magazine.
Opticann will carry the trusted C.A.R.P. Recommended Seal and C.A.R.P. members will receive an exclusive 15 percent discount when they purchase any of the following Opticann CB4 medical cannabis products:
CB4 Relief: Oral CBD Capsules with VESIsorb® Technology
CB4 Relief-T: Oral CBD and THC Capsules with VESIsorb® Technology
CB4 Relief Deep Rub Gel
CB4 Derma Topical
CB4 Clear Face Gel
CB4 Control: CBD/CBDA Rapid Acting Sublingual Filmstrip with Versafilm® technology from IntelGenx
C.A.R.P. patients must register at Opticann.ca in order to receive the discount for purchase of these products with a medical document.
“Understanding the utility of medical cannabis is increasingly important to older Canadians for the treatment of conditions including chronic pain, anxiety and lack of sleep. These new products especially play a role in displacing less-desirable drugs that may come with complications and side effects,” said C.A.R.P. President and ZoomerMedia Founder, Moses Znaimer. “As this new therapeutic industry blossoms in Canada, misleading information can be very detrimental to patients’ health and well-being, as is self-medication through the recreational system. After surveying the market carefully, we can confidently recommend Opticann’s highly professional evidence-based research approach in developing unique and highly effective CB4 medical products that are convenient and safe.
“This exciting new partnership with C.A.R.P., an organization dedicated to improving the lives of mature Canadians, will educate people on scientific research and the role of cannabinoids in treating serious and chronic healthcare conditions. We know the C.A.R.P. demographic is a large and highly engaged group that can benefit from well designed and scientifically tested medical cannabis products proven to be effective,” commented Umar Syed, President of the Medical Division at Heritage Cannabis.
In consideration for this partnership, Opticann-Heritage will pay ZoomerMedia cash and a portion in Heritage equity at $0.10 per share.
“We believe in Opticann’s industry leading medical products and leadership and as such, have taken an equity position in the company,” continued Moses.
Opticann’s suite of CB4 medical cannabis products are based on trusted pharmaceutical technology platforms that are optimized for the effective delivery of cannabinoids – for maximum effect and to minimize unwanted effects. Opticann products are based on innovative pharmaceutical technology that deliver the best results consistently, safely, and in convenient dosage forms (capsules, sublingual filmstrips, and topicals). These dosage forms are tested and optimized to deliver active ingredients for effective results. Opticann products also contain the highest quality ingredients and are thoroughly quality tested for consistency.
Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, feelgood., CB4 and ArthroCBD.